Preserve Your Vision
with Izervay
The #1 prescribed FDA-approved treatment to slow geographic atrophy (GA) and help protect your sight longer.
Hope for Geographic Atrophy
Izervay (avacincaptad pegol) is a breakthrough prescription eye injection designed to treat geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD). Approved by the FDA in August 2023, Izervay is the only GA treatment proven to significantly slow disease progression in two Phase 3 clinical trials (GATHER1 and GATHER2), reducing the rate of vision loss as early as six months. By targeting the C5 protein, Izervay protects retinal cells, helping you maintain your independence and vision for longer.
Izervay: A trusted choice for slowing GA progression.
Why Choose Izervay?
Izervay empowers patients with GA to take control of their vision health. Here’s why it stands out:
- Proven Efficacy: Clinically shown to slow GA progression, helping preserve central vision for activities like reading and driving.
- FDA-Approved: The #1 prescribed treatment for new GA patients, with over 210,000 vials distributed by December 2024.
- Safe Administration: Administered monthly by retina specialists with numbing and monitoring to ensure comfort and safety.
- Financial Support: Izervay My Way offers assistance for eligible patients, whether insured, uninsured, or on Medicare.
Protect the moments that matter with Izervay.
Take the First Step
Geographic atrophy affects an estimated 1.5 million people in the U.S., often leading to irreversible vision loss. With Izervay, you can act early to slow GA progression and preserve your sight. Don’t delay—talk to your retina specialist today to see if Izervay is right for you. Learn about financial assistance through Izervay My Way and connect with support communities like Prevent Blindness.